Table 4.

Patients with disease activity in the intent-to-treat (ITT) population

	Year 1 (n = 187)	Year 2 (n = 163)	Year 3 (n = 147)	Year 4 (n = 139)
Patients with disease activity, n (%)a	82 (43.8%)	43 (26.4%)c	42 (28.6%)c	35 (25.2%)c
Patients who relapsed, n (%)b	23 (28.0%)	20 (46.5%)	15 (35.7%)	11 (31.4%)
Patients with CDW, n (%)b	19 (23.2%)	8 (18.6%)	10 (23.8%)	2 (5.7%)
Patients with ≥ 1 Gd+ lesion, n (%)b	8 (9.8%)	6 (14.0%)	4 (9.5%)	9 (25.7%)
Patients with ≥ 1 new or enlarging T2 lesion, n (%)b	53 (64.6%)	18 (41.9%)	20 (47.6%)	22 (62.9%)

CDW confirmed disability worsening, Gd+ gadolinium enhancing

^aIncluded patients who displayed disease activity on ≥ 1 no evidence of disease activity (NEDA) parameter

^bThe denominator is the number of patients with disease activity in the respective year

^cNumber of patients who previously had disease activity (year 2: n = 27; year 3: n = 27; year 4: n = 24)